Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 211

1.

4-Thiazolidinone Derivatives as MMP Inhibitors in Tissue Damage: Synthesis, Biological Evaluation and Docking Studies.

Incerti M, Crascì L, Vicini P, Aki E, Yalcin I, Ertan-Bolelli T, Cardile V, Graziano ACE, Panico A.

Molecules. 2018 Feb 14;23(2). pii: E415. doi: 10.3390/molecules23020415.

2.

Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status.

Baverel PG, Dubois VFS, Jin CY, Zheng Y, Song X, Jin X, Mukhopadhyay P, Gupta A, Dennis PA, Ben Y, Vicini P, Roskos L, Narwal R.

Clin Pharmacol Ther. 2018 Apr;103(4):631-642. doi: 10.1002/cpt.982. Epub 2018 Feb 2.

3.

Controlling the bioactivity of a peptide hormone in vivo by reversible self-assembly.

Ouberai MM, Dos Santos ALG, Kinna S, Madalli S, Hornigold DC, Baker D, Naylor J, Sheldrake L, Corkill DJ, Hood J, Vicini P, Uddin S, Bishop S, Varley PG, Welland ME.

Nat Commun. 2017 Oct 18;8(1):1026. doi: 10.1038/s41467-017-01114-1.

4.

A computational multiscale agent-based model for simulating spatio-temporal tumour immune response to PD1 and PDL1 inhibition.

Gong C, Milberg O, Wang B, Vicini P, Narwal R, Roskos L, Popel AS.

J R Soc Interface. 2017 Sep;14(134). pii: 20170320. doi: 10.1098/rsif.2017.0320.

5.

Model-Based Discovery and Development of Biopharmaceuticals: A Case Study of Mavrilimumab.

Wang B, Wu CY, Jin D, Vicini P, Roskos L.

CPT Pharmacometrics Syst Pharmacol. 2018 Jan;7(1):5-15. doi: 10.1002/psp4.12245. Epub 2017 Nov 23.

6.

Dose-Exposure-Response Relationship of the Investigational Anti-Interleukin-13 Monoclonal Antibody Tralokinumab in Patients With Severe, Uncontrolled Asthma.

Baverel PG, White N, Vicini P, Karlsson MO, Agoram B.

Clin Pharmacol Ther. 2018 May;103(5):826-835. doi: 10.1002/cpt.803. Epub 2017 Sep 28.

PMID:
28758192
7.

Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.

Planken S, Behenna DC, Nair SK, Johnson TO, Nagata A, Almaden C, Bailey S, Ballard TE, Bernier L, Cheng H, Cho-Schultz S, Dalvie D, Deal JG, Dinh DM, Edwards MP, Ferre RA, Gajiwala KS, Hemkens M, Kania RS, Kath JC, Matthews J, Murray BW, Niessen S, Orr ST, Pairish M, Sach NW, Shen H, Shi M, Solowiej J, Tran K, Tseng E, Vicini P, Wang Y, Weinrich SL, Zhou R, Zientek M, Liu L, Luo Y, Xin S, Zhang C, Lafontaine J.

J Med Chem. 2017 Apr 13;60(7):3002-3019. doi: 10.1021/acs.jmedchem.6b01894. Epub 2017 Mar 29.

PMID:
28287730
8.

Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future.

Darwich AS, Ogungbenro K, Vinks AA, Powell JR, Reny JL, Marsousi N, Daali Y, Fairman D, Cook J, Lesko LJ, McCune JS, Knibbe C, de Wildt SN, Leeder JS, Neely M, Zuppa AF, Vicini P, Aarons L, Johnson TN, Boiani J, Rostami-Hodjegan A.

Clin Pharmacol Ther. 2017 May;101(5):646-656. doi: 10.1002/cpt.659. Epub 2017 Apr 4. Review.

PMID:
28182269
9.

Metadynamics for Perspective Drug Design: Computationally Driven Synthesis of New Protein-Protein Interaction Inhibitors Targeting the EphA2 Receptor.

Incerti M, Russo S, Callegari D, Pala D, Giorgio C, Zanotti I, Barocelli E, Vicini P, Vacondio F, Rivara S, Castelli R, Tognolini M, Lodola A.

J Med Chem. 2017 Jan 26;60(2):787-796. doi: 10.1021/acs.jmedchem.6b01642. Epub 2017 Jan 5.

PMID:
28005388
11.

A quantitative systems pharmacology model of blood coagulation network describes in vivo biomarker changes in non-bleeding subjects.

Lee D, Nayak S, Martin SW, Heatherington AC, Vicini P, Hua F.

J Thromb Haemost. 2016 Dec;14(12):2430-2445. doi: 10.1111/jth.13515.

PMID:
27666750
12.

Found in Translation: Maximizing the Clinical Relevance of Nonclinical Oncology Studies.

Spilker ME, Chen X, Visswanathan R, Vage C, Yamazaki S, Li G, Lucas J, Bradshaw-Pierce EL, Vicini P.

Clin Cancer Res. 2017 Feb 15;23(4):1080-1090. doi: 10.1158/1078-0432.CCR-16-1164. Epub 2016 Aug 22.

13.

Geometrical modified nesbit corporoplasty to correct different types of penile curvature: description of the surgical procedure based on geometrical principles and long-term results.

Vicini P, Di Nicola S, Antonini G, De Berardinis E, Gentile V, De Marco F.

Int J Impot Res. 2016 Nov;28(6):209-215. doi: 10.1038/ijir.2016.28. Epub 2016 Aug 11.

PMID:
27511302
14.

Multi-scale Modeling in Clinical Oncology: Opportunities and Barriers to Success.

Yankeelov TE, An G, Saut O, Luebeck EG, Popel AS, Ribba B, Vicini P, Zhou X, Weis JA, Ye K, Genin GM.

Ann Biomed Eng. 2016 Sep;44(9):2626-41. doi: 10.1007/s10439-016-1691-6. Epub 2016 Jul 6. Review.

15.

INSIST-ED: Italian Society of Andrology registry on penile prosthesis surgery. First data analysis.

Pescatori E, Alei G, Antonini G, Avolio A, Bettocchi C, Bitelli M, Boezio F, Cai T, Caraceni E, Carrino M, Colombo F, Conti E, Corvasce A, Dehò F, Fiordelise S, Ghidini N, Italiano E, La Pera G, Liguori G, Maretti C, Mondaini N, Natali A, Negro C, Palmieri A, Palumbo F, Paradiso M, Polito M, Pozza D, Silvani M, Tamai A, Timpano M, Utizi L, Varvello F, Vicini P, Vitarelli A, Franco G.

Arch Ital Urol Androl. 2016 Jul 4;88(2):122-7. doi: 10.4081/aiua.2016.2.122.

16.

Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return.

Russo S, Callegari D, Incerti M, Pala D, Giorgio C, Brunetti J, Bracci L, Vicini P, Barocelli E, Capoferri L, Rivara S, Tognolini M, Mor M, Lodola A.

Chemistry. 2016 Jun 6;22(24):8048-52. doi: 10.1002/chem.201600993. Epub 2016 May 3.

PMID:
27139720
17.

Multiscale Modeling in the Clinic: Drug Design and Development.

Clancy CE, An G, Cannon WR, Liu Y, May EE, Ortoleva P, Popel AS, Sluka JP, Su J, Vicini P, Zhou X, Eckmann DM.

Ann Biomed Eng. 2016 Sep;44(9):2591-610. doi: 10.1007/s10439-016-1563-0. Epub 2016 Feb 17. Review.

18.

Translational modeling and simulation approaches for molecularly targeted small molecule anticancer agents from bench to bedside.

Yamazaki S, Spilker ME, Vicini P.

Expert Opin Drug Metab Toxicol. 2016;12(3):253-65. doi: 10.1517/17425255.2016.1141895. Review.

PMID:
26799750
19.

Three-component hydraulic penile prosthesis malfunction due to penile fibrolipoma secondary to augmentative phalloplasty: A case report.

Antonini G, Vicini P, De Berardinis E, Pacchiarotti A, Gentile V, Perito P.

Arch Ital Urol Androl. 2016 Jan 14;87(4):339-41. doi: 10.4081/aiua.2015.4.339.

20.

Penile prosthesis implant for erectile dysfunction: A new minimally invasive infrapubic surgical technique.

Antonini G, Busetto GM, De Berardinis E, Giovannone R, Vicini P, Gentile V, Perito PE.

Arch Ital Urol Androl. 2016 Jan 14;87(4):322-4. doi: 10.4081/aiua.2015.4.322.

21.

The Role of Aggregates of Therapeutic Protein Products in Immunogenicity: An Evaluation by Mathematical Modeling.

Yin L, Chen X, Tiwari A, Vicini P, Hickling TP.

J Immunol Res. 2015;2015:401956. doi: 10.1155/2015/401956. Epub 2015 Nov 22.

22.

Minimally invasive infrapubic inflatable penile prosthesis implant for erectile dysfunction: evaluation of efficacy, satisfaction profile and complications.

Antonini G, Busetto GM, De Berardinis E, Giovannone R, Vicini P, Del Giudice F, Conti SL, Gentile V, Perito PE.

Int J Impot Res. 2016 Jan-Feb;28(1):4-8. doi: 10.1038/ijir.2015.33. Epub 2015 Dec 10.

23.

Organ Dose Estimates for Hyperthyroid Patients Treated with (131)I: An Update of the Thyrotoxicosis Follow-Up Study.

Melo DR, Brill AB, Zanzonico P, Vicini P, Moroz B, Kwon D, Lamart S, Brenner A, Bouville A, Simon SL.

Radiat Res. 2015 Dec;184(6):595-610. doi: 10.1667/RR14160.1. Epub 2015 Nov 18.

PMID:
26579944
24.

Precision medicine in the age of big data: The present and future role of large-scale unbiased sequencing in drug discovery and development.

Vicini P, Fields O, Lai E, Litwack ED, Martin AM, Morgan TM, Pacanowski MA, Papaluca M, Perez OD, Ringel MS, Robson M, Sakul H, Vockley J, Zaks T, Dolsten M, Søgaard M.

Clin Pharmacol Ther. 2016 Feb;99(2):198-207. doi: 10.1002/cpt.293. Epub 2015 Dec 19. Review.

PMID:
26536838
25.

Ignorance is not bliss: Statistical power is not probability of trial success.

Zierhut ML, Bycott P, Gibbs MA, Smith BP, Vicini P.

Clin Pharmacol Ther. 2016 Apr;99(4):356-9. doi: 10.1002/cpt.257. Epub 2015 Oct 23.

PMID:
26331445
26.

Using a Systems Pharmacology Model of the Blood Coagulation Network to Predict the Effects of Various Therapies on Biomarkers.

Nayak S, Lee D, Patel-Hett S, Pittman DD, Martin SW, Heatherington AC, Vicini P, Hua F.

CPT Pharmacometrics Syst Pharmacol. 2015 Jul;4(7):396-405. doi: 10.1002/psp4.50. Epub 2015 Jun 19.

27.

Mathematical modeling of receptor occupancy data: A valuable technology for biotherapeutic drug development.

Spilker ME, Singh P, Vicini P.

Cytometry B Clin Cytom. 2016 Mar;90(2):230-6. doi: 10.1002/cyto.b.21318. Epub 2015 Oct 1. Review.

28.

Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products.

Yin L, Chen X, Vicini P, Rup B, Hickling TP.

Cell Immunol. 2015 Jun;295(2):118-26. doi: 10.1016/j.cellimm.2015.03.002. Epub 2015 Mar 14. Review.

PMID:
25880103
29.

Reply by authors.

Antonini G, Vicini P, Sanalone S, Garaffa G, Vitarelli A, De Berardinis E, Von Heland M, Giovannone R, Casciani E, Gentile V.

Arch Ital Urol Androl. 2014 Dec;86(4):304. No abstract available.

PMID:
25803879
30.

2-Benzisothiazolylimino-5-benzylidene-4-thiazolidinones as protective agents against cartilage destruction.

Crascì L, Vicini P, Incerti M, Cardile V, Avondo S, Panico A.

Bioorg Med Chem. 2015 Apr 1;23(7):1551-6. doi: 10.1016/j.bmc.2015.02.002. Epub 2015 Feb 11.

PMID:
25725607
31.

Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration.

McCune JS, Vicini P, Salinger DH, O'Donnell PV, Sandmaier BM, Anasetti C, Mager DE.

Cancer Chemother Pharmacol. 2015 Jan;75(1):67-75. doi: 10.1007/s00280-014-2618-2. Epub 2014 Nov 6.

32.

Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase.

Yamazaki S, Lam JL, Zou HY, Wang H, Smeal T, Vicini P.

Drug Metab Dispos. 2015 Jan;43(1):54-62. doi: 10.1124/dmd.114.061143. Epub 2014 Oct 27.

33.

A review of quantitative modeling of B cell responses to antigenic challenge.

Hickling TP, Chen X, Vicini P, Nayak S.

J Pharmacokinet Pharmacodyn. 2014 Oct;41(5):445-59. doi: 10.1007/s10928-014-9388-7. Epub 2014 Oct 19. Review.

PMID:
25326873
34.

Large bowel infarct following antegrade scrotal sclerotherapy for varicocele: A case report.

Vicini P, Di Pierro GB, Grande P, Voria G, Antonini G, De Marco F, Di Nicola S, Gentile V.

Can Urol Assoc J. 2014 Sep;8(9-10):E641-3. doi: 10.5489/cuaj.1822.

35.

A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 2-model applications.

Chen X, Hickling TP, Vicini P.

CPT Pharmacometrics Syst Pharmacol. 2014 Sep 3;3:e134. doi: 10.1038/psp.2014.31.

36.

A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 1-theoretical model.

Chen X, Hickling TP, Vicini P.

CPT Pharmacometrics Syst Pharmacol. 2014 Sep 3;3:e133. doi: 10.1038/psp.2014.30.

37.

A new efficient route to 7-aryl-6-fluoro-8-nitroquinolones as potent antibacterial agents.

Al-Trawneh SA, El-Abadelah MM, Al-Abadleh MM, Zani F, Incerti M, Vicini P.

Eur J Med Chem. 2014 Oct 30;86:364-7. doi: 10.1016/j.ejmech.2014.08.065. Epub 2014 Aug 26.

PMID:
25180924
38.

Translation of anticancer efficacy from nonclinical models to the clinic.

Stroh M, Duda DG, Takimoto CH, Yamazaki S, Vicini P.

CPT Pharmacometrics Syst Pharmacol. 2014 Aug 6;3:e128. doi: 10.1038/psp.2014.28.

39.

Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1.

Yamazaki S, Lam JL, Zou HY, Wang H, Smeal T, Vicini P.

J Pharmacol Exp Ther. 2014 Oct;351(1):67-76. doi: 10.1124/jpet.114.217141. Epub 2014 Jul 29.

40.

Whither pharmacometrics?: present state and future choices.

Vicini P, Smith BP.

Clin Pharmacol Ther. 2014 Jun;95(6):567-71. doi: 10.1038/clpt.2014.72.

PMID:
24842634
41.

Use of inflatable penile prostheses AMS CX with momentary squeeze in a patient with Peyronie's disease after removal of two previously implanted penile prostheses.

Vicini P, De Marco F, Antonini G, De Berardinis E, Giovannone R, Pecoraro S, Azzarri L, Gentile V.

Arch Ital Urol Androl. 2014 Mar 28;86(1):46-7. doi: 10.4081/aiua.2014.1.46.

42.

Penile fracture: penoscrotal approach with degloving of penis after Magnetic Resonance Imaging (MRI).

Antonini G, Vicini P, Sansalone S, Garaffa G, Vitarelli A, De Berardinis E, Von Heland M, Giovannone R, Casciani E, Gentile V.

Arch Ital Urol Androl. 2014 Mar 28;86(1):39-40. doi: 10.4081/aiua.2014.1.39.

43.

UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations.

Hassan-Mohamed I, Giorgio C, Incerti M, Russo S, Pala D, Pasquale EB, Zanotti I, Vicini P, Barocelli E, Rivara S, Mor M, Lodola A, Tognolini M.

Br J Pharmacol. 2014 Dec;171(23):5195-208. doi: 10.1111/bph.12669. Epub 2014 Aug 28.

44.

Design synthesis and antibacterial activity studies of new thiadiazoloquinolone compounds.

Al-Qawasmeh RA, Abadleh MM, Zahra JA, El-Abadelah MM, Albashiti R, Zani F, Incerti M, Vicini P.

J Enzyme Inhib Med Chem. 2014 Dec;29(6):777-85. doi: 10.3109/14756366.2013.855925. Epub 2014 Feb 10.

PMID:
24506209
45.

RTP801 gene expression is differentially upregulated in retinopathy and is silenced by PF-04523655, a 19-Mer siRNA directed against RTP801.

Rittenhouse KD, Johnson TR, Vicini P, Hirakawa B, Kalabat D, Yang AH, Huang W, Basile AS.

Invest Ophthalmol Vis Sci. 2014 Mar 4;55(3):1232-40. doi: 10.1167/iovs.13-13449.

PMID:
24458146
46.

Pharmacometrics and Systems Pharmacology Software Tutorials and Use: Comments and Guidelines for PSP Contributions.

Vicini P, Friberg LE, van der Graaf PH, Rostami-Hodjegan A.

CPT Pharmacometrics Syst Pharmacol. 2013 Dec 18;2:e86. doi: 10.1038/psp.2013.60.

47.

Penile subcutaneous fibrolipoma postaugmentative phalloplasty.

Vicini P, De Marco F, Letizia P, Alei L, Antonini G, Alei G, Gentile V.

Case Rep Urol. 2013;2013:696314. doi: 10.1155/2013/696314. Epub 2013 Sep 30.

48.

Synthesis and structure-activity relationships of amino acid conjugates of cholanic acid as antagonists of the EphA2 receptor.

Russo S, Incerti M, Tognolini M, Castelli R, Pala D, Hassan-Mohamed I, Giorgio C, De Franco F, Gioiello A, Vicini P, Barocelli E, Rivara S, Mor M, Lodola A.

Molecules. 2013 Oct 21;18(10):13043-60. doi: 10.3390/molecules181013043.

49.

The development of a fully-integrated immune response model (FIRM) simulator of the immune response through integration of multiple subset models.

Palsson S, Hickling TP, Bradshaw-Pierce EL, Zager M, Jooss K, O'Brien PJ, Spilker ME, Palsson BO, Vicini P.

BMC Syst Biol. 2013 Sep 28;7:95. doi: 10.1186/1752-0509-7-95.

50.

A mathematical model of the effect of immunogenicity on therapeutic protein pharmacokinetics.

Chen X, Hickling T, Kraynov E, Kuang B, Parng C, Vicini P.

AAPS J. 2013 Oct;15(4):1141-54. doi: 10.1208/s12248-013-9517-z. Epub 2013 Aug 30.

Supplemental Content

Loading ...
Support Center